Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registra...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), ou NASH, et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enregistrement...
In this note we provide a summary of the feedback from Inventiva's FY23 conference call. The company's CEO provided an overview of Inventiva's progress in 2023 and early 2024. This was followed by Q&A which largely focussed on the resumption of recruitment in the phase 3 (NATiV3) trial with lanifibranor in MASH, strength of the lanifibranor dataset vs. competitors, as well as partnering and funding options to reach NATiV3 topline readout expected in 1H26. Read our morning note on Inventiva's FY2...
Inventiva reported FY23 results with a cash position of € 26.9m (YE22: € 86.7m), which together with the 2nd EIB tranche of € 25m announced in January 2024, provides the company with a cash runway until the beginning of 3Q24. This is sufficient to fund Inventiva beyond the NATiV3 last patient first visit (albeit just about), expected by 1H24 – we view this as an important milestone as it would provide timeline certainty by pinning the topline readout to 1H26. We point to the improved sentiment a...
Inventiva announces the nomination of Andre Turenne as Director Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne’s appointment wil...
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur Daix (France), Long Island City (New York, États-Unis), le 28 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), ou NASH, et d’autres maladies avec un besoin médical non satisfait, a annoncé aujourd'hui la nomination d'Andre Turenne à son Conseil d'Administration. La nomination de M. Ture...
Inventiva reports its 2023 full-year results Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In September 2023, Inventiva entered into an exclusive licensing agreement with Hepalys to develop and commercialize lanifibranor in Japan and South Korea In January 2024, Inventiva received the second tranche...
Inventiva publie ses résultats annuels 2023 Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022Trésorerie et équivalents de trésorerie de 26,9 millions d’euros, dépôt à court terme de 0,01 million d’euros1 et dépôt à long-terme de 9,0 millions d’euros2 au 31 décembre 2023, contre respectivement 86,7 millions d’euros, 1,0 million d’euros et 0,7 million d’euros au 31 décembre 2022 En septembre 2023, Inventiva a conclu un accord de licence exclusif avec Hepalys pour développer et commercialiser lanifibranor au Japon et ...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), ou NASH, et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui que son équipe de direction présentera les résultats financiers 2023 de l...
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Compan...
Following the announcement of positive phase 2 (LEGEND) results with lanifibranor + empagliflozin in MASH and T2D, hitting on the primary and multiple secondary endpoints, Inventiva's stock traded down approx. -11%. We believe this response is unjustified given that the results showcase lanifibranor's potential as a combination therapy, further boosting the candidate's positioning in MASH. In addition, Inventiva presented results from payer and prescriber surveys, which we see as further support...
Inventiva reported positive topline data from the phase 2 (LEGEND) trial of lanifibranor + empagliflozin in MASH and T2D. In addition to hitting on the primary endpoint (HbA1c), we note the stabilisation of weight as well as improvements in secondary outcomes (e.g. liver enzymes and fibrosis markers). In our view, the results boost lanifibranor's positioning in MASH, demonstrating its potential as a combination therapy, which is important given that combinations will likely be required to addres...
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis.Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight througho...
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2 LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’hémoglobine HbA1c dans les groupes recevant lanifibranor seul ou en combinaison avec empagliflozine, par rapport au groupe placebo.Un effet statistique a également été démontré pour plusieurs marqueurs de lésions hépatiques, du métabolisme glycémique et des lipides, ainsi que sur la stéatos...
In Inventiva related news, competitor Madrigal Pharmaceuticals (not covered) gained FDA accelerated approval for Rezdiffra (resmetirom, THR-ß agonist) in MASH (F2/F3). Rezdiffra's approval is the first ever in MASH, and in our view is a positive development for the MASH space as a whole, paving a regulatory path for other companies, such as Inventiva, to follow. Note that Inventiva is conducting a phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH (F2/F3), with last patient first ...
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.